Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Breakfree-SLE: CC-97540 (BMS-986353) NEX-T CAR T Cells in Active SLE
jRCT2033250759Phase 2Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2026
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
01
Overview
Phase 2, open-label, single-arm trial of BMS-986353 in systemic lupus erythematosus (SLE) and lupus nephritis (LN), sponsored by Bristol Myers Squibb. Primary endpoint: Drug-free DORIS remission. Started Feb 2026; status: recruiting.
02
Drugs
BMS-986353
03
Conditions
systemic lupus erythematosus (SLE)lupus nephritis (LN)
Beyond the preview
Go deeper on jRCT2033250759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2033250759.